肝硬化患者中糖尿病与肝性脑病的关联
前瞻性队列纳入240例肝硬化患者,随访中位17个月。糖尿病独立关联研究入组时隐匿性肝性脑病的存在及随访期间显性肝性脑病的发生;HbA1c≥6.5%者隐匿性肝性脑病OR 2.264(95%CI 1.002-5.118)、显性肝性脑病HR 4.116(95%CI 1.791-9.459)。
要点
- 肝硬化合并糖尿病患者隐匿性肝性脑病及随访期显性肝性脑病风险独立升高。
- 血糖控制较差(HbA1c≥6.5%)者隐匿性肝性脑病OR 2.264、显性肝性脑病HR 4.116。
- 作者认为良好血糖控制可能是减轻该重要并发症的潜在靶点。
核心结论
- 糖尿病可能与肝硬化患者隐匿性肝性脑病的存在及显性肝性脑病的发生风险升高相关(原文用may)。
- 作者认为充分的血糖控制可能是减轻该重要并发症的潜在靶点。
研究设计与样本
- 前瞻性队列研究,纳入240例肝硬化患者,随访中位17个月。
- 隐匿性肝性脑病通过Portosystemic Hepatic Encephalopathy Score的病理性结果诊断。
- 采用逻辑回归或Cox回归模型分析隐匿性肝性脑病存在或显性肝性脑病发生的预测因素。
主要发现
- 研究入组时65例(27.1%)患者有糖尿病,隐匿性肝性脑病检出率为33.3%。
- 糖尿病患者较无糖尿病患者肝功能更保留(MELD 9 vs 10;P=0.043)。
- 校正混杂因素后,糖尿病独立关联研究入组时隐匿性肝性脑病的存在及随访期间显性肝性脑病的发生。
- 上述关联在独立的倾向评分加权回归模型中得到确认。
- 亚组分析中,血糖控制较差(HbA1c≥6.5%)的患者隐匿性肝性脑病风险更高(OR 2.264,95%CI 1.002-5.118),显性肝性脑病风险更高(HR 4.116,95%CI 1.791-9.459)。
临床怎么用
- 原文未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Diabetes mellitus may lead to increased serum ammonia and systemic inflammation thereby promoting hepatic encephalopathy (HE). AIM: To investigate the potential association between diabetes mellitus/glycaemic control and the presence of covert HE as well as the development of overt HE in a prospective setting. METHODS: A total of 240 patients with liver cirrhosis were included into this prospective cohort study and followed for a median of 17 months. Covert HE was diagnosed by pathological results in the Portosystemic Hepatic Encephalopathy Score. Predictors for the presence of covert HE or the development of overt HE were analysed using logistic regression or Cox-regression models. RESULTS: At study inclusion, 65 patients (27.1%) presented with diabetes mellitus and covert HE was detected in 33.3%. Patients with diabetes mellitus had a more preserved liver function as compared to patients without diabetes mellitus (MELD 9 vs 10; P = 0.043). In regression analyses after adjustment for confounders, diabetes mellitus was independently associated with the presence of covert HE at study inclusion and the development of overt HE during follow-up. These associations were confirmed in separate propensity-score-weighted regression models. In subgroup analyses, patients with worse glycaemic control (HbA1c >= 6.5%) had a pronounced risk for covert HE (OR 2.264, 95% CI 1.002-5.118) and overt HE (HR 4.116, 95% CI 1.791-9.459). CONCLUSIONS: Diabetes mellitus may associate with higher risk for the presence of covert HE and the development of overt HE in patients with liver cirrhosis. Adequate glycaemic control may be a potential target to attenuate this important complication.
引用
- Labenz C, Nagel M, Kremer WM, et al. Association between diabetes mellitus and hepatic encephalopathy in patients with cirrhosis. Aliment Pharmacol Ther. 2020. PMID: 32598080. doi:10.1111/apt.15915
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。